Dermorphin is a naturally occurring heptapeptide distinguished by its exceptional binding affinity for the mu-opioid receptor (MOR) and unique inclusion of D-alanine at position 2. Investigated exclusively in preclinical settings, this compound serves as a pivotal tool for exploring peptide-receptor interaction kinetics, enzymatic degradation resistance, and central nervous system signaling pathways.
Dermorphin is a naturally occurring heptapeptide distinguished by its exceptional binding affinity for the mu-opioid receptor (MOR) and unique inclusion of D-alanine at position 2. Investigated exclusively in preclinical settings, this compound serves as a pivotal tool for exploring peptide-receptor interaction kinetics, enzymatic degradation resistance, and central nervous system signaling pathways.
The dermorphin research peptide is a high-affinity mu-opioid receptor agonist originally isolated from the skin of South American Phyllomedusa frogs. Composed of seven amino acids (H-Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2), dermorphin is notable for containing a D-amino acid within its primary sequence, which confers exceptional resistance to endogenous peptidases during in vitro and in vivo assays.
Synthesized under strict laboratory conditions, dermorphin is supplied strictly as a purified research-grade compound for non-human preclinical investigation. In vitro binding studies demonstrate that its affinity for the mu-opioid receptor is several orders of magnitude higher than endogenous opioid peptides like Met-enkephalin, making it a critical reference material in neuropharmacology, receptor binding, and peptide stability research.
Dermorphin possesses the amino acid sequence Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2, featuring a C-terminal amidation and a D-alanine residue at the second position. The presence of D-alanine is a rare structural modification among eukaryotic peptides, synthesized post-translationally via enzymatic isomerization in its natural origin. This specific D-stereoisomer architecture alters the spatial conformation of the N-terminal sequence, rendering the N-terminal peptide bond resistant to cleavage by standard aminopeptidases.
In enzymatic degradation assays, the incorporation of D-amino acids significantly prolongs peptide half-life in extracellular matrix surrogates and serum assays compared to all-L-amino acid analogs. Researchers studying peptide stabilization techniques frequently utilize dermorphin as a structural model for designing degradation-resistant therapeutic scaffolds. Understanding how the Tyr-D-Ala motif maintains precise structural fit within the orthosteric binding pocket of GPCRs continues to provide key insights for computational biophysics and rational drug design.
Preclinical binding assays indicate that dermorphin exhibits nanomolar and sub-nanomolar affinity ($K_i$ values typically $< 1 \text{ nM}$) for the mu-opioid receptor ($\mu$-OR), demonstrating minimal cross-reactivity with delta ($\delta$) or kappa ($\kappa$) opioid receptor subtypes. Upon binding to the orthosteric pocket of the G-protein coupled receptor (GPCR), dermorphin initiates heterotrimeric $G_i/G_o$ protein coupling, inhibiting adenylyl cyclase activity and reducing intracellular cyclic AMP (cAMP) levels.
In vitro functional assays further show that dermorphin activation leads to the opening of inwardly rectifying potassium channels ($GIRK$) and the inhibition of voltage-gated calcium channels. Researchers evaluating receptor trafficking and desensitization use dermorphin to measure $\beta$-arrestin recruitment versus G-protein biased signaling pathways. In cellular models expressing human or rodent MOR, the kinetic profile of dermorphin-induced receptor internalization provides actionable data regarding receptor recycling rates and signal termination mechanisms.
In rodent models, supraspinal and intrathecal administration of dermorphin has been extensively evaluated to assess central nociceptive signaling pathways. Preclinical literature demonstrates potent antinociceptive activity in tail-flick and hot-plate assays, outperforming morphine on a molar basis. Because dermorphin exhibits limited passive permeability across the blood-brain barrier due to its charge and hydrophilic character, systemic assays often examine specialized delivery mechanisms, such as nanoparticle encapsulation or co-administration with transport enhancers.
Additional research focuses on the peripheral effects of dermorphin in isolated tissue preparations, such as guinea pig ileum (GPI) and mouse vas deferens (MVD) bioassays. These classical organ-bath experiments allow investigators to dissect receptor subtype selectivity and quantify competitive antagonism using selective blockers like naloxone. The published data consistently highlight dermorphin as one of the most potent naturally derived peptide agonists identified for the mu-opioid receptor system.
When evaluating peptidergic ligands for receptor binding and neurochemical assays, researchers often compare dermorphin against other modified or endogenous peptides in the same structural and functional class. A comparative analysis highlights distinct binding preferences, stability profiles, and target selectivity across various neurological targets.
For instance, while dermorphin maintains strict selectivity for the mu-opioid receptor due to its Tyr-D-Ala core, synthetic analogs like dalargin incorporate D-Leu modifications optimized for peripheral mu- and delta-receptor interaction. Similarly, endogenous sequences such as met-enkephalin exhibit much rapid enzymatic degradation due to their natural L-amino acid backbone. In contrast, non-opioid central nervous system research tools such as dsip or regulatory tissue peptides like bpc-157 operate through entirely distinct receptor pathways, underlining the necessity of precise ligand selection depending on whether the experimental focus is GPCR signal transduction, neuropeptide stability, or cell cytoprotection. Researchers can explore the full range of options in our comprehensive all-peptides library.
Dermorphin is supplied as a lyophilized (freeze-dried) powder to maximize chemical stability during storage and transit. For laboratory reconstitution, strict aseptic technique must be maintained inside a certified laminar flow hood. Dermorphin exhibits high solubility in aqueous buffers, including sterile water for injection, phosphate-buffered saline (PBS, pH 7.4), and dilute acetic acid solutions.
To reconstitute, allow the glass vial to equilibrate to room temperature prior to introducing the solvent. Slowly inject the desired volume of sterile diluent against the inner glass wall of the vial to minimize turbulent agitation and foam formation. Gently swirl or invert the vial until complete dissolution is achieved; vortexing should be avoided as mechanical shear forces can induce peptide aggregation or denaturation. Stock solution concentrations between $0.5 \text{ mg/mL}$ and $2.0 \text{ mg/mL}$ are recommended for bench working solutions.
Lyophilized dermorphin should be stored at $-20^\circ\text{C}$ or $-80^\circ\text{C}$ in a dry location, shielded from light exposure. Under these conditions, the unconstituted peptide maintains its chemical integrity and enzymatic activity for up to 24 months. Desiccant packs should be kept in the storage container to prevent atmospheric moisture absorption, which can trigger hydrolytic degradation over extended periods.
Once reconstituted into an aqueous stock solution, dermorphin exhibits finite stability. Aliquots intended for short-term use (within 24–48 hours) may be kept at $4^\circ\text{C}$. For long-term experimental protocols, stock solutions must be divided into single-use micro-aliquots and stored at $-80^\circ\text{C}$ to prevent repetitive freeze-thaw cycles. Freezing and thawing cycles accelerate physical aggregation and hydrolytic cleavage of the amide bond, compromising assay reproducibility.
To ensure rigor and reproducibility across preclinical assays, research peptides must undergo rigorous analytical verification prior to laboratory deployment. Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) is utilized to determine overall chemical purity, measuring the relative area under the curve (AUC) for the target peptide peak against trace impurities or synthesis side-products.
Electrospray Ionization Mass Spectrometry (ESI-MS) or MALDI-TOF analysis is simultaneously performed to confirm exact molecular weight ($803.9 \text{ Da}$ for dermorphin, $C_{40}H_{50}N_8O_{10}$). Mass spectral data verify the correct primary sequence and confirm the absence of truncated sequences, deletion peptides, or residual protecting groups from the solid-phase peptide synthesis (SPPS) process. High-purity batches exceeding $\ge 98\%$ chemical purity are standard for demanding in vitro kinetic assays.
PX1 Research manufactures all research peptides in US-based, GMP-compliant facilities subject to stringent quality management protocols. Every production lot of dermorphin is independently tested by an ISO 17025-accredited third-party laboratory. Each shipment includes a comprehensive Certificate of Analysis (COA) detailing HPLC purity chromatograms, mass spectrometry profiles, and quantified endotoxin levels ($< 0.01 \text{ EU/\mu g}$).
Our fulfillment infrastructure provides same-day dispatch for orders placed Monday through Friday before cut-off times, shipping directly from specialized California and Arizona distribution hubs to maintain cold-chain integrity. Institutional laboratories, university departments, and bulk purchasers requiring multi-gram quantities or custom synthesis lots can access scaled pricing structures and dedicated account managers via our wholesale portal. Additional compound documentation and technical datasheets are available in the PX1 research library.
What is dermorphin research peptide?
Dermorphin is a heptapeptide (Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2) originally isolated from frog skin, widely studied in preclinical research as a highly selective, high-affinity agonist for the mu-opioid receptor.
Why does dermorphin contain a D-amino acid?
Dermorphin contains D-alanine at position 2. This stereoisomeric configuration confers high resistance to cleavage by endogenous proteolytic enzymes, significantly extending its stability in biological assays compared to all-L-amino acid peptides.
How is dermorphin reconstituted for laboratory research?
Dermorphin should be reconstituted using sterile water, bacteriostatic water, or isotonic buffers like PBS (pH 7.4). Solvents should be added gently down the side of the vial, followed by mild rotation or swirling to avoid shear-induced aggregation.
What purity level is guaranteed for PX1 Research dermorphin?
Every lot of dermorphin supplied by PX1 Research undergoes RP-HPLC and MS analysis to confirm chemical purity equal to or exceeding 98.0%, accompanied by a lot-specific Certificate of Analysis.
How should reconstituted dermorphin stock solutions be stored?
Reconstituted solutions should be divided into single-use aliquots and stored at -80°C. Repeated freeze-thaw cycles must be avoided to prevent structural degradation and preserve ligand-receptor binding capacity.
What are the primary target receptors studied with dermorphin?
Dermorphin primarily targets the mu-opioid receptor (MOR) with nanomolar affinity, exhibiting negligible cross-reactivity with delta or kappa opioid receptor subtypes in receptor binding assays.
Is dermorphin tested for endotoxin content?
Yes. PX1 Research subjects all peptide lots to Chromogenic LAL testing in an ISO 17025 accredited laboratory to ensure endotoxin levels remain below standard analytical thresholds (<0.01 EU/µg).
Can dermorphin be purchased for human administration or therapeutic use?
No. Dermorphin is strictly manufactured and distributed as a research peptide for in vitro laboratory assays and animal models. Human consumption, clinical use, or medical application is strictly prohibited.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.